References
- Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
- Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16(1):5–24. doi:10.1634/theoncologist.2010-0190.
- Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–534. doi:10.1200/JCO.2007.12.7837.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621.
- Murphy WJ, Longo DL. Immunotherapy adoption in community setting hindered by costs, biomarker identification. HemOnc Today; [published 2015 Nov 10; cited 2015 Dec 28]. Available from: http://www.healio.com/hematology-oncology/melanoma-skin-cancer/news/print/hemonc-today/%7Bd230fb64-7785-4b81-b796-7a96b75e44ab%7D/immunotherapy-adoption-in-community-setting-hindered-by-costs-biomarker-identification
- The Centers for Medicare & Medicaid Services, Usa M. Medicare provider utilization and payment data: physician and other supplier; [published 2014 Apr 23; cited 2015 Feb 4]. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Physician-and-Other-Supplier.html
- The Henry J. Kaiser Family Foundation. Number of Medicare advantage plan enrollees as a share of total Medicare beneficiaries: 2013; 2014 [cited 2015 Dec 1]. Available from: http://kff.org/medicare/state-indicator/enrollees-as-a-of-total-medicare-population/
- American Cancer Society. Cancer facts & figures; 2013 [published 2013; cited 2013 Oct 16]. Available from: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013
- United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. United States Cancer Statistics: 1999–2012 incidence, WONDER online database; 2015 [cited 2015 Dec 1]. Available from: http://wonder.cdc.gov/cancer-v2012.html
- National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. Surveillance, epidemiology, and end results (SEER) program (www.seer.cancer.gov) SEER*Stat database: incidence - SEER 18 Regs Research Data + Hurricane Katrina impacted Louisiana cases, Nov 2014 Sub (2000-2012) <Katrina/Rita population adjustment> - linked to county attributes - total U.S., 1969–2013 counties. 2015.
- Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3–IV-18. doi:10.1097/01.MLR.0000020942.47004.03.
- Goldberg NH, Schneeweiss S, Kowal MK, et al. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305(17):1786–1789. doi:10.1001/jama.2011.539.
- Bristol-Myers Squibb Company. U.S. full prescribing information of YERVOY; [published 2015; cited 2015 Dec 11]. Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdf
- Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. doi:10.1200/JCO.2009.23.4799.
- New immunotherapy costing $1 million a year. Medscape; [cited 2016 Mar 18]. Available from: http://www.medscape.com/viewarticle/845707